Brave Bison Group 2.5p £32.3m (BBSN.L)
The digital advertising and technology services company today reports its unaudited interim results for the six months ended 30 June 2024. Revenue increased 1% to £10.1m (H1 2023: £10.0m), Adjusted profit before tax increased 20% to £1.8m (H1 2023: £1.5m) and net cash exclu Lease Liabilities increased 57% to £6.8m (H1 2023: £4.3m). The Board expects to exceed current market forecasts for FY24 as a result of better than anticipated trading at Brave Bison Performance and increased profitability at SocialChain.
European Green Transition 13p £18.8m (EGT.L)
A company developing green economy assets in Europe which aims to capitalise on the opportunity created by the green energy transition announces that it has completed the low-cost drill programme at its Olserum Rare Earth Element (REE) Project in Sweden. Successful completion of 13 holes for c.1,500 metres of diamond core drilling ahead of schedule and below budget at the Olserum REE project in Sweden. The Directors are encouraged by the work performed with visual inspection of the drill core indicating broad alteration zones and intervals with intersections of visible phosphate mineralisation, which the Directors believe host the REEs. Core logging is now complete and lab-based analysis to assess REE concentration is due to commence in late September 2024, with results expected later in H2-2024.
EQTEC 0.975p £2.5m (EQT.L)
The technology innovator powering distributed, decarbonised, new energy infrastructure through its waste-to-value solutions for hydrogen, biofuels, and energy generation announces further to the announcements of 4 September 2024 of the Fundraise, the completion of the WRAP Retail Offer at the Issue Price. The WRAP Retail Offer, which closed at 4:30 p.m. on Friday 6 September 2024, has raised gross proceeds of £72,528.15. The net proceeds of the Fundraise, along with the Company's existing cash resources, will be deployed for general working capital purposes and to accelerate the implementation of its strategy.
ImmuPharma 1.48p £6.2m (IMM.L)
The specialist drug discovery and development company announces its interim results for the six months ended 30 June 2024. Loss for the period decreased to £0.4m (30 June 2023: £0.8m), research and development costs decreased to £0.5m (30 June 2023: £0.8m) and the cash balance of £1.1m as at 30 June 2024 (30 June 2023: £0.2m). The Company have continued their focus on tight cost controls and maximising the use of outsourcing to keep their committed overhead costs to the minimum. This is illustrated very clearly in the reduction of their operating loss for the period to £0.4m down from £0.8m for the same period last year. They have also strengthened the balance sheet and extended their cash runway by successfully selling their shareholding in Incanthera, whilst still retaining a further 7.3m warrants.
Norman Broadbent 6.875p £4.6m (NBB.L)
The Executive Search and Interim Management firm announces its unaudited interim results for the six months ended 30 June 2024. Revenue decreased 18% to £5.0m (H1 2023: £6.1m), Underlying EBITDA of £0.13m, £0.1m bad debt provision (H1 2023: £0.27m) and cash and cash equivalents of £48k (30 June 2023: £81k). While the market remains tough, as reported in recent announcements by virtually all companies in our sector, several industry indicators suggest a gradual stabilisation is underway. They are seeing pockets of increased activity and are encouraged by the gradually improving retainer income so far in Q3 2024.
Oncimmune Holdings 22.6p £16.8m (ONC.L)
The autoantibody profiling Company providing research services to the pharmaceutical and biotechnology industry to enable the delivery of precision medicine provides a trading update following strong commercial progress since its last update on 21 May 2024. As announced on 9 August 2024, following a successful pilot carried out for a major pharmaceutical company, Oncimmune has entered into an agreement for a major new project with that pharmaceutical company, with a contract value of at least US$1.5m, which will utilise a technological breakthrough achieved by Oncimmune's scientific team. As further announced on 2 September 2024, another major pharmaceutical company, for whom Oncimmune is already a preferred supplier, has entered into a new $0.7m project, focused on a rare immune related disease, with the initial samples to be analysed already being held by Oncimmune. Oncimmune has also entered into contracts for three other new projects since its last update. Two contracts are with a US biotech to analyse multi-omic data from its clinical trials. This is a new area for Oncimmune and a testament to its strong data analytics capability. The third contract is through a contract research organisation with whom Oncimmune has a long standing relationship, with the project providing IgA autoantibody analysis for a European biotech as a follow on to previous work carried out for that customer.
Sunda Energy 0.075p £19.1m (SNDA.L)
The exploration and appraisal company focused on gas assets in Southeast Asia announces its unaudited interim results for the six months ended 30 June 2024. Loss before tax £996k (30 June 2023: £847k), cash and cash equivalents £4.55m (30 June 2023: £4.62m). In February 2024, the Company raised £2,993,000 net (£3,264,000 gross) from the issue of new share capital by way of a Placing, Subscription and WRAP Retail Offer. During June 2024, the Bank Guarantee for the Chuditch PSC was increased from US$1.0m to US$2.5m (net US$2.0m) as the Company prepared to enter Contract Year 3 of the PSC, with its increased work commitments.
Synectics 195p £34.7m (SNX.L)
The advanced security and surveillance systems announces that it has been awarded a further contract, worth approximately US$3.2m, relating to the upgrade and expansion of the surveillance system at a major gaming resort in South-East Asia. This Contract is in addition to the US$10m contract award announced on 18 June 2024. The Customer has been using Synergy, the Company's proprietary software platform, since 2014 and the Contracts will expand and upgrade the Customer's existing system to the latest version of Synergy. The Contract is expected to be delivered in the year ending 30 November 2025.
SulNOx Group 31p £37.7m (AQSE: SNOX)
A greentech Company which specialises in providing responsible solutions towards decarbonisation of liquid hydrocarbon fuels announces its Final Results and Audited Annual Report and Accounts for the Year to 31 March 2024. Revenue increased to £544k (2023: £203k), loss before tax decreased to £1.86m (2023: £1.90m) and cash at bank and in hand was £2.15m (2023: £649k).
The Pebble Group 60p £99.4m (PEBB.L)
The provider of digital commerce, products and related services to the global promotional products industry announces its unaudited results for the six months ended 30 June 2024. Revenue decreased 4% to £60.8m (H1 2023: £63.3m), adjusted EBITDA decreased 1% to £7.4m (H1 2023: £7.5m) and net cash increased to £4.9m (H1 2023: £4.2m). The Board expects FY 24 results to deliver on its market expectations .
.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
